Global Interferons Market 2024 , Forecast To 2033
7 Mar, 2024
The interferons market has seen steady growth, from $9.17 billion in 2023 to $9.54 billion in 2024, with a CAGR of 4.0%. This growth is fueled by factors like viral infections and cancer treatment. The market is projected to continue growing steadily, reaching $11.98 billion by 2028, driven by factors such as immunotherapy advancements and viral outbreak preparedness, alongside trends like expanding applications and biopharmaceutical innovation.
Global Interferons Market Key Driver
The rise in cancer is expected to boost the growth of the interferon market (1). With cancer being characterized by the uncontrollable development of abnormal cells and an anticipated 609,360 cancer deaths and 1.9 million new cases in the US in 2022, there is a growing demand for interferons in treating various types of cancer, including melanoma and certain leukemias, thus driving market growth.
Get A Free Sample Of The Global Interferons Market ReportGlobal Interferons Market Segments
The interferons market covered in this report is segmented –
1) By Type: Inteferon Alpha, Inteferon Beta, Inteferon Gamma
2) By Application: Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
By Geography: The countries covered in the interferons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
North America was the largest region in the interferons market in 2023. Middle East is expected to be the fastest-growing region in the interferons market during the forecast period. The regions covered in the interferons market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Interferons Industry Players
Roche Holding AG; Merck & Co. Inc.; Bristol-Myers Squibb Company; Biogen Inc.; Bayer AG; Zydus Cadila Health Care Limited; Novartis AG; Pfizer Inc.; Biosidus S.A.; Nanogen Biopharmaceutical Co. Ltd.; Amega Biotech Inc.; Rhein Minapharm Biogenetics S.A.E.; PROBIOMED S.A. de C.V.; Schering-Plough Corporation; 3SBio Inc.; AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Genentech Inc.; GlaxoSmithKline plc; Johnson & Johnson; Novo Nordisk A/S; Sanofi S.A.; Shire plc; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Biocad; Cipla Limited; Dr. Reddy's Laboratories Ltd.; Hetero Drugs Limited
Get The Full Global Interferons Market Report
Interferons Market Overview
Interferons refer to a natural substance that supports the body's immune system in the battle against illness, including cancer. White blood cells and other cells in the body produce interferons, but they can also be produced in a lab for use in treating various disorders.